Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Bone metastases are common in patients with advanced lung cancer and can have devastating
consequences. Preventing or delaying bone metastases may improve outcomes. Bisphosphonates
are inhibitors of osteoclast-mediated bone resorption. The current indications for
bisphosphonates include the treatment of metabolic disorders of bone metabolism (e.g.,
osteoporosis and Paget's disease), the treatment of hypercalcaemia of malignancy (HCM), and
the prevention of skeletal-related events(SREs）from malignant bone disease. Clinical trials
also confirm that bisphosphonates, and zoledronic acid（ZOL) in particular, can prevent bone
loss from cancer treatment.There is also emerging evidence that the benefits of
bisphosphonate therapy in the oncology setting are more extensive. This study will evaluate
whether the addition of ZOL 4 mg every 3 months for up to 1 years in patients with stage
IIIB/IV lung cancer could reduce the rate of bone metastases ,improve progression-free
survival (PFS) and overall survival(OS), and delay time to bone metastases .